Clinical Trial Detail

NCT ID NCT02623972
Title A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

breast cancer

Therapies

Cyclophosphamide + Doxorubicin + Eribulin

Age Groups: senior adult

Additional content available in CKB BOOST